• Cohen, A.D., Zhou, P., Chou, J., Teruya-Feldstein, J., Reich, L., Hassoun, H., Levine, B., Filippa, D.A., Riedel, E., Kewalramani, T., Stubblefield, M.D., Fleisher, M., Nimer, S. & Comenzo, R.L. (2007) Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/− thalidomide for systemic light-chain amyloidosis: results of a phase II trial. British Journal Haematology, 139, 224233.
  • Comenzo, R.L., Sanchorawala, V., Fisher, C., Akpek, G., Farhat, M., Cerda, S., Berk, J.L., Dember, L.M., Falk, R., Finn, K., Skinner, M. & Vosburgh, E. (1999) Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM + G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. British Journal Haematology, 104, 553559.
  • Dispenzieri, A., Gertz, M.A., Kyle, R.A., Lacy, M.Q., Burritt, M.F., Therneau, T.M., Greipp, P.R., Witzig, T.E., Lust, J.A., Rajkumar, S.V., Fonseca, R., Zeldenrust, S.R., McGregor, C.G. & Jaffe, A.S. (2004) Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. Journal of Clinical Oncology, 22, 37513757.
  • Dispenzieri, A., Lacy, M.Q., Zeldenrust, S.R., Hayman, S.R., Kumar, S.K., Geyer, S.M., Lust, J.A., Allred, J.B., Witzig, T.E., Rajkumar, S.V., Greipp, P.R., Russell, S.J., Kabat, B. & Gertz, M.A. (2007) The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood, 109, 465470.
  • Falk, R.H., Comenzo, R.L. & Skinner, M. (1997) The systemic amyloidoses. New England Journal of Medicine, 337, 898909.
  • Kastritis, E., Anagnostopoulos, A., Roussou, M., Toumanidis, S., Pamboukas, C., Migkou, M., Tassidou, A., Xilouri, I., Delibasi, S., Psimenou, E., Mellou, S., Terpos, E., Nanas, J. & Dimopoulos, M.A. (2007) Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica, 92, 13511358.
  • Maurer, M.S., Raina, A., Hesdorffer, C., Bijou, R., Colombo, P., Deng, M., Drusin, R., Haythe, J., Horn, E., Lee, S.H., Marboe, C., Naka, Y., Schulman, L., Scully, B., Shapiro, P., Prager, K., Radhakrishnan, J., Restaino, S. & Mancini, D. (2007) Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure. Transplantation, 83, 539545.
  • Merlini, G. & Stone, M.J. (2006) Dangerous small B-cell clones. Blood, 108, 25202530.
  • Pepys, M.B. (2006) Amyloidosis. Annual Review of Medicine, 57, 223241.
  • Sanchorawala, V., Wright, D.G., Seldin, D.C., Falk, R.H., Finn, K.T., Dember, L.M., Berk, J.L., Quillen, K., Anderson, J.J., Comenzo, R.L. & Skinner, M. (2004) High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplantation, 33, 381388.
  • Wechalekar, A.D., Goodman, H.J., Lachmann, H.J., Offer, M., Hawkins, P.N. & Gillmore, J.D. (2007) Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood, 109, 457464.
  • Zhou, P., Comenzo, R.L., Olshen, A.B., Bonvini, E., Koenig, S., Maslak, P.G., Fleisher, M., Hoffman, J., Jhanwar, S., Young, J.W., Nimer, S.D. & Boruchov, A.M. (2008) CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy. Blood, 111, 34033406.